Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 11/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | KMO | O15229 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2564093 | 0.90 | BRD4 (0.41) | BRD4PDE7A | |
| SCHEMBL2558198 | 0.89 | GRM2 (0.36) | BRD4GRM2ALDH1A1KMOMEN1 | |
| SCHEMBL2568131 | 0.85 | TSHR (0.46) | ALDH1A1MEN1KMT2APDE7A | |
| SCHEMBL2561572 | 0.79 | TP53 (0.38) | BRD4 | |
| SCHEMBL3004967 | 0.79 | BRD4 (0.38) | BRD4 | |
| SCHEMBL2564410 | 0.75 | TSHR (0.41) | ALDH1A1MEN1KMT2A | |
| SCHEMBL2566434 | 0.75 | BRD4 (0.43) | BRD4 | |
| SCHEMBL2573319 | 0.74 | BRD4 (0.40) | BRD4KMO | |
| SCHEMBL2997987 | 0.74 | TSHR (0.40) | ALDH1A1MEN1KMT2A | |
| SCHEMBL2566036 | 0.74 | TP53 (0.38) | ALDH1A1MEN1KMT2APDE7A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2382218-A1 | DELTA-5-DESATURASE INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2011-11-02 | — | — | EP | disclosed |
| WO-2010087467-A1 | DELTA-5-DESATURASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-05 | — | — | WO | disclosed |
| US-20100190747-A1 | Fused ring compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-07-29 | — | — | US | disclosed |
| US-20100190747-A1 | Fused ring compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-07-29 | — | — | US | disclosed |
| US-20100190747-A1 | Fused ring compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190747-A1 | Fused ring compound and use thereof | CYP46A1, LTB4R2, PTGES | BRD4 365/4885GRM2 3235/4885ALDH1A1 875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.